NIH Taps Appistry to Commercialize Analysis Pipeline for Undiagnosed Diseases Program | GenomeWeb

NEW YORK (GenomeWeb News) – Appistry said today that it has been selected by the National Institutes of Health's Undiagnosed Diseases program (UDP) to create a commercial version of a genetic analysis pipeline developed at the NIH for studying genetic mutations that underlie many rare and undiagnosed diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.